SIGNIFOR
Total Payments
$17.2M
Transactions
250
Doctors
37
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $331,230 | 9 | 2 |
| 2021 | $42,277 | 10 | 0 |
| 2020 | $1.6M | 13 | 1 |
| 2019 | $1.5M | 35 | 2 |
| 2018 | $2.9M | 44 | 2 |
| 2017 | $10.7M | 139 | 35 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.1M | 223 | 99.9% |
| Consulting Fee | $8,682 | 4 | 0.1% |
| Travel and Lodging | $641.12 | 3 | 0.0% |
| Food and Beverage | $365.25 | 20 | 0.0% |
Payments by Type
Research
$17.1M
223 transactions
General
$9,688
27 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL MULTI CENTER PASIREOTIDE ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED PASIREOTIDE STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED PASIREOTIDE TREATMENT | Novartis Pharmaceuticals Corporation | $6.1M | 0 |
| A 3 ARM RANDOMIZED PHASE II TRIAL EVALUATING SINGLE AGENT AND COMBINED EFFICACY OF PASIREOTIDE AND EVEROLIMUS IN ADULT PATIENTS WITH RADIOIODINE REFRACTORY DIFFERENTIATED AND MEDULLARY THYROID CANCER | Novartis Pharmaceuticals Corporation | $3.9M | 0 |
| A MULTI CENTER RANDOMIZED OPEN LABEL PHASE IV STUDY TO INVESTIGATE THE MANAGEMENT OF PASIREOTIDE INDUCED HYPERGLYCEMIA WITH INCRETIN BASED THERAPY OR INSULIN IN ADULT PATIENTS WITH CUSHINGS DISEASE OR ACROMEGALY | Novartis Pharmaceuticals Corporation | $3.4M | 0 |
| A RANDOMIZED PLACEBO CONTROLLED CLINICAL TRIAL OF SOM230 PASIREOTIDE LAR IN SEVERE POLYCYSTIC LIVER DISEASE | Novartis Pharmaceuticals Corporation | $1.3M | 0 |
| PHASE II STUDY OF PASIREOTIDE LAR IN PATIENTS WITH METASTATIC NEUROENDOCRINE CARCINOMAS | Novartis Pharmaceuticals Corporation | $571,969 | 0 |
| PREVENTION OF GASTROINTESTINAL TOXICITY FROM TOTAL BODY IRRADIATION OR HIGH DOSE CHEMOTHERAPY WITH SOM230 | Novartis Pharmaceuticals Corporation | $422,574 | 0 |
| PILOT STUDY OF PASIREOTIDE LAR TREATMENT OF SILENT CORTICOTROPH PITUITARY TUMORS AND EFFECTS ON PLASMA LEVELS OF POMC | Novartis Pharmaceuticals Corporation | $385,966 | 0 |
| STIMULATION OF SSTR2 AND SSTR5 AS A PATHOPHYSIOLOGICAL MECHANISMS IN HYPERGLYCEMIA | Novartis Pharmaceuticals Corporation | $232,736 | 0 |
| PHASE IB AND OR II STUDY OF PASIREOTIDE EVEROLIMUS AND SELECTIVE INTERNAL RADIOEMBOLIZATION THERAPY SIRT FOR UNRESECTABLE NEUROENDOCRINE HEPATIC METASTASES | Novartis Pharmaceuticals Corporation | $184,251 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $95,915 | 17 |
| NON INTERVENTIONAL STUDY FOR THE GENERATION OF LONG TERM SAFETY AND EFFICACY DATA OF PASIREOTIDE SC IN PATIENTS WITH CUSHINGS DISEASE POST AUTHORIZATION SAFETY STUDY | Novartis Pharmaceuticals Corporation | $60,449 | 0 |
| A PHASE III MULTICENTER RANDOMIZED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF DOUBLE BLIND PASIREOTIDE LAR 40 MG AND PASIREOTIDE LAR 60 MG VERSUS OPEN LABEL OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY | Novartis Pharmaceuticals Corporation | $28,526 | 0 |
| A RANDOMIZED DOUBLE BLIND MULTICENTER PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PASIREOTIDE LAR IN PATIENTS WITH CUSHINGS DISEASE | Novartis Pharmaceuticals Corporation | $24,119 | 0 |
| A PHASE II TRIAL TO ASSESS THE EFFICACY AND SAFETY OF PASIREOTDE SC ALONE AND IN COMBINATION WITH CABERGOLINE IN PATIENTS WITH CUSHINGS DISEASE | Novartis Pharmaceuticals Corporation | $21,975 | 0 |
| A PHASE I MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF PASIREOTIDE SOM230 LAR IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS NETS | Novartis Pharmaceuticals Corporation | $16,894 | 0 |
| A TWO PART MULTICENTER PLACEBO CONTROLLED ACTIVE COMPARATOR CONTROLLED SINGLE DOSE STUDY IN ACUTE EPISODIC AND CHRONIC CLUSTER HEADACHE TO EVALUATE THE SAFETY AND EFFICACY OF SOM230 SC | Novartis Pharmaceuticals Corporation | $16,547 | 0 |
| A MULTICENTER RANDOMIZED BLINDED EFFICACY AND SAFETY STUDY OF PASIREOTIDE LAR VS OCTREOTIDE LAR IN PATIENTS WITH METASTATIC CARCINOID TUMORS WHOSE DISEASE RELATED SYMPTOMS ARE INADEQUATELY CONTROLLED BY SOMATOSTATIN ANALOGUES | Novartis Pharmaceuticals Corporation | $14,202 | 0 |
| SEASCAPE SAFETY AND EXPANDED ACCESS STUDY IN CUSHINGS DISEASE TO ALLOCATE PASIREOTIDE EXPERTISE | Novartis Pharmaceuticals Corporation | $6,510 | 0 |
| AN OPEN LABEL MULTICENTER SINGLE ARM STUDY OF PASIREOTIDE LAR IN PATIENTS WITH RARE TUMORS OF NEUROENDOCRINE ORIGIN | Novartis Pharmaceuticals Corporation | $6,424 | 0 |
| A MULTICENTER RANDOMIZED BLINDED STUDY TO ASSESS SAFETY AND EFFICACY OF PASIREOTIDE LAR VS OCTREOTIDE LAR IN PATIENTS WITH ACTIVE ACROMEGALY | Novartis Pharmaceuticals Corporation | $5,459 | 0 |
Top Doctors Receiving Payments for SIGNIFOR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Palo Alto, CA | $17.0M | 156 |
| , MD | Endocrinology, Diabetes & Metabolism | Albuquerque, NM | $18,850 | 2 |
| , MD | Internal Medicine | Albuquerque, NM | $18,850 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Pittsburgh, PA | $11,287 | 4 |
| , MD | Internal Medicine | Boston, MA | $10,687 | 14 |
| , MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $9,033 | 11 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $8,199 | 6 |
| , MD | Internal Medicine | Los Angeles, CA | $8,199 | 6 |
| , MD | Neurological Surgery | Los Angeles, CA | $6,336 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $5,025 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $2,198 | 4 |
| , MD | Endocrinology, Diabetes & Metabolism | Stanford, CA | $1,863 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Rochester, NY | $1,863 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Torrance, CA | $1,863 | 3 |
| , M.D | Internal Medicine | Torrance, CA | $1,863 | 3 |
| , MD | Internal Medicine | Miami, FL | $1,863 | 3 |
| Ekaterina Manuylova | Endocrinology, Diabetes & Metabolism | Salem, OR | $1,863 | 3 |
| Justin Cetas | — | Portland, OR | $1,499 | 2 |
| , M.D | Neurology | Las Vegas, NV | $532.00 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Miami, FL | $335.15 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Long Island City, NY | $22.15 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $18.46 | 1 |
| , MD | Internal Medicine | Atlanta, GA | $18.46 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Owosso, MI | $16.93 | 1 |
| , MD | Internal Medicine | Orlando, FL | $16.28 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $17.2M
- Total Doctors 37
- Transactions 250
About SIGNIFOR
SIGNIFOR is a drug associated with $17.2M in payments to 37 healthcare providers, recorded across 250 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2022. In 2022, $331,230 was paid across 9 transactions to 2 doctors.
The most common payment nature for SIGNIFOR is "Unspecified" ($17.1M, 99.9% of total).
SIGNIFOR is associated with 20 research studies, including "AN OPEN LABEL MULTI CENTER PASIREOTIDE ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED PASIREOTIDE STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED PASIREOTIDE TREATMENT" ($6.1M).